Cara Therapeutics 将来の成長

Future 基準チェック /26

Cara Therapeuticsは、37.3%と46.4%でそれぞれ年率37.3%で利益と収益が成長すると予測される一方、EPSはgrowで53.1%年率。

主要情報

37.3%

収益成長率

53.1%

EPS成長率

Pharmaceuticals 収益成長	19.6%
収益成長率	46.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

LSE:0HTC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	7	-37	N/A	-36	3
12/31/2025	6	-46	N/A	-52	3
12/31/2024	7	-74	N/A	-63	3
9/30/2024	9	-96	-77	-74	N/A
6/30/2024	11	-111	-83	-80	N/A
3/31/2024	17	-123	-91	-88	N/A
12/31/2023	21	-119	-94	-92	N/A
9/30/2023	21	-117	-99	-98	N/A
6/30/2023	27	-112	-104	-104	N/A
3/31/2023	43	-84	-88	-88	N/A
12/31/2022	42	-85	-79	-79	N/A
9/30/2022	39	-89	-57	-56	N/A
6/30/2022	49	-66	-45	-45	N/A
3/31/2022	26	-93	-62	-62	N/A
12/31/2021	23	-88	-60	-60	N/A
9/30/2021	134	24	23	23	N/A
6/30/2021	123	8	15	16	N/A
3/31/2021	129	14	9	9	N/A
12/31/2020	135	8	-6	-5	N/A
9/30/2020	28	-99	-119	-119	N/A
6/30/2020	24	-115	-123	-123	N/A
3/31/2020	24	-113	-120	-120	N/A
12/31/2019	20	-106	-109	-109	N/A
9/30/2019	21	-98	-102	-102	N/A
6/30/2019	20	-85	-97	-97	N/A
3/31/2019	18	-79	-31	-31	N/A
12/31/2018	13	-74	-22	-22	N/A
9/30/2018	8	-68	-9	-9	N/A
6/30/2018	3	-61	N/A	1	N/A
3/31/2018	N/A	-53	N/A	-52	N/A
12/31/2017	1	-58	N/A	-55	N/A
9/30/2017	1	-66	N/A	-57	N/A
6/30/2017	1	-65	N/A	-60	N/A
3/31/2017	1	-69	N/A	-59	N/A
12/31/2016	0	-57	N/A	-47	N/A
9/30/2016	0	-45	N/A	-38	N/A
6/30/2016	3	-38	N/A	-33	N/A
3/31/2016	3	-31	N/A	-26	N/A
12/31/2015	4	-25	N/A	-21	N/A
9/30/2015	5	-19	N/A	-23	N/A
6/30/2015	3	-21	N/A	-20	N/A
3/31/2015	3	-19	N/A	-20	N/A
12/31/2014	3	-18	N/A	-18	N/A
9/30/2014	3	-16	N/A	-17	N/A
6/30/2014	3	-14	N/A	-16	N/A
3/31/2014	12	-6	N/A	2	N/A
12/31/2013	12	-3	N/A	3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0HTC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0HTC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 0HTC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0HTCの収益 ( 46.4% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0HTCの収益 ( 46.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0HTCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cara Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.52 loss in 3Q 2023)

New major risk - Financial position

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.58 loss in 2Q 2023)

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.49 loss in 1Q 2023)

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Full year 2023 earnings released: US$2.19 loss per share (vs US$1.59 loss in FY 2022)

New major risk - Revenue and earnings growth

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

New major risk - Financial position

Third quarter 2023 earnings released: US$0.52 loss per share (vs US$0.43 loss in 3Q 2022)

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$0.078 loss in 2Q 2022)

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.52 loss in 1Q 2022)

Full year 2022 earnings released: US$1.59 loss per share (vs US$1.74 loss in FY 2021)

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.02 loss in 3Q 2021)

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Cara Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Key Executive recently sold US$111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Kapruvia® Gets Approval in Switzerland with Additional Regulatory Decisions

Second quarter 2022 earnings released: US$0.078 loss per share (vs US$0.61 loss in 2Q 2021)

Cara Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Cara Therapeutics, Inc. Announces Positive Topline Results from Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Officer, Effective on or About June 15, 2022

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.47 loss in 1Q 2021)

Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) and Cara Therapeutics, Inc. Announces the European Commission Has Granted Marketing Authorization to Kapruvia

Cara Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Cara Therapeutics, Inc Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announce CHMP Recommend Approval of Kapruvia for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

Independent Director recently sold US$131k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.35 loss in 3Q 2020)

Co-Founder recently sold US$309k worth of stock

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.47 loss per share (vs US$0.62 loss in 1Q 2020)

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Investor sentiment deteriorated over the past week

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Revenue beats expectations

Full year 2020 earnings released: EPS US$0.18 (vs US$2.49 loss in FY 2019)

Cara Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘